- PrVYZULTA® Added Under Alberta,
Saskatchewan, Manitoba, New
Brunswick, Nova Scotia,
Newfoundland and Labrador, and Federal Non-Insured Health
Benefits (NIHB) Plans
LAVAL, QC, Sept. 24, 2020 /CNW Telbec/ - Bausch +
Lomb., a leading global eye health business of Bausch Health
Companies Inc. (NYSE: BHC) (TSX: BHC), announced that
PrVYZULTA® (latanoprostene bunod
ophthalmic solution, 0.024% w/w), which is indicated for the
reduction of intraocular pressure (IOP) in patients with open-angle
glaucoma or ocular hypertensioni, now has expanded
public drug program reimbursement in the provinces of Alberta, Saskatchewan, Manitoba, New
Brunswick, Nova Scotia,
Newfoundland and Labrador and as part of the federal
Non-Insured Health Benefits (NIHB).
These provinces join Ontario,
which made VYZULTA available to patients in December 2019.ii
Affecting over 400,000 Canadians, glaucoma is a disease of the
optic nerve and the leading cause of blindness in North America.iii
"We are pleased that a growing number of provinces and the
federal government recognize the impact of glaucoma on patients and
the health care system and are increasing access to VYZULTA, a new
option that can help patients manage this potentially life-altering
condition and possibly preserve eyesight," said Richard
Lajoie, President and General Manager of Bausch
Health, Canada. "Bausch + Lomb is very proud of the part we
play in helping Canadians live better by enabling them to see
better with our products."
VYZULTA has a dual mechanism of action for lowering intraocular
pressure by increasing outflow of aqueous humor through both
uveoscleral and trabecular meshwork
routes.i VYZULTA is to be
administered once daily.
"VYZULTA is the first molecule introduced
into Canada in approximately 20 years with a
unique mode of action for reducing eye pressure, and
is an important advancement in the medical management of
glaucoma because it offers a novel therapeutic option for
our patients," said Dr. David Yan,
Ophthalmologist-in-Chief, Sinai Health System.
For Canadians, glaucoma is one of the leading causes of
irreversible blindness.iv Glaucoma is defined as a
group of eye diseases that slowly and progressively affect the
optic nerve,v which can lead to irreversible vision
loss. Open-angle glaucoma is the most common form of the disease
and is associated with elevated pressure caused by a backup of
fluid in the eye.vi
"The governments of Alberta,
Saskatchewan, Manitoba, Ontario, New
Brunswick, Nova Scotia,
Newfoundland and Labrador, and the federal government, through
the Non-Insured Health Benefits program are showing their
commitment to advancing the standard of care for glaucoma patients
by making Vyzulta available to patients on public formularies,"
said Doug Earle, President & CEO, Fighting Blindness
Canada. "On behalf of the constituents of Fighting Blindness
Canada, I am heartened to see that people in these provinces and
jurisdictions living with open-angle glaucoma now have access to
another treatment option that they can discuss with their
optometrist or ophthalmologist."
VYZULTA received its Notice of Compliance (NOC) from Health
Canada on Dec. 27, 2018 and is currently covered by most
private insurance plans in Canada.
About Bausch + Lomb
Bausch + Lomb, a leading global
eye health business of Bausch Health Companies Inc., is solely
focused on helping people see better to live better. Its core
businesses include over-the-counter products, dietary supplements,
eye care products, ophthalmic pharmaceuticals, contact lenses, lens
care products, ophthalmic surgical devices and instruments. Bausch
+ Lomb develops, manufactures and markets one of the most
comprehensive product portfolios in the industry, which is
available in approximately 100 countries. For more information,
visit www.bausch.ca.
About Bausch Health
Bausch Health Companies Inc.
(NYSE/TSX: BHC) is a global company whose mission is to
improve people's lives with our health care products. We develop,
manufacture and market a range of pharmaceutical, medical device
and over-the-counter products, primarily in the therapeutic areas
of eye health, gastroenterology and dermatology. We are
delivering on our commitments as we build an innovative company
dedicated to advancing global health.
In Canada, our areas of focus include eye health,
dermatology and cardio metabolic. More information can be found
at www.bauschhealth.ca.
______________________________
|
i
|
PrVyzulta® Product
Monograph, dated December 27, 2018.
|
ii
|
Ontario Drug Benefit
Formulary/Comparative Drug Index Edition 43 Summary of Changes
– December 2019 Effective December 20,
2019,p.5; http://www.health.gov.on.ca/en/pro/programs/drugs/formulary43/summary_edition43_20191213.pdf
|
iii
|
CADTH Common Drug
Review - Patient Input. Latanorpostene Bunod (Vyzulta). December
12, 2018.
https://www.cadth.ca/sites/default/files/cdr/relatedinfo/SR0590%20Vyzulta%20-%20Patient%20Group%20Input_January%208%2C%202019.pdf Accessed:
September 18, 2020
|
iv
|
Quigley HA, Broman
AT. The number of people with glaucoma worldwide in 2010 and
2020. British Journal of
Ophthalmology. 2006;90(3):262v Horton JC.
Disorders of the Eye. In: Kasper D, Fauci A, Hauser S, Longo D,
Jameson JL, Loscalzo J, eds. Harrison's Principles of
Internal Medicine, 19e. New York, NY: McGraw-Hill
Education; 2015.
|
vi
|
Canadian
Ophthalmological Society Glaucoma Clinical Practice Guideline
Expert Committee; Canadian Ophthalmological Society. Canadian
Ophthalmological Society evidence-based clinical practice
guidelines for the management of glaucoma in the adult eye. Can J
Ophthalmol. 2009;44 Suppl 1:S7-S93.
|
SOURCE Bausch + Lomb Canada